CHPA's voluntary plan to address concerns surrounding the safety and efficacy of OTC oral pediatric cough and cold medicines. CHPA, on behalf of its member companies, commits to the following initiatives.
CHPA comments on the proposed rule, which proposes new warning and other labeling requirements for internal analgesic, antipyretic, and antirheumatic OTC drug products.
FDA issued a proposed rule on labeling requirements for OTC human drugs. The announcement proposed a definition for “convenience-size” OTC drug packages as well as the option of alternative labeling requirements for these products. CHPA welcomes the opportunity to comment on the proposed rule changes.
The PCPC and CHPA are pleased to provide these comments in response to FDA's proposed amendment to the final monograph for OTC sunscreen drug products for human use.
This meta-analysis aimed to compare single-dose 10 mg phenylephrine and placebo separately in adult patients with acute nasal congestion due to the common cold.
This summary report presents the key findings of a national survey of American adults regarding the use of over-the-counter cough remedies to alleviate cough symptoms resulting from the flu, a cold, or other respiratory ailment.
